{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:32Z","timestamp":1786985432178,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmcl.2025.130166","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:38:10Z","timestamp":1741304290000},"page":"130166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development of 9H-purine scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation"],"prefix":"10.1016","volume":"122","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2025.130166_bb0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bmcl.2025.130166_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.bi.61.070192.002301","article-title":"Animal-cell cycles and their control","volume":"61","author":"Norbury","year":"1992","journal-title":"Annu. Rev. Biochem."},{"issue":"36","key":"10.1016\/j.bmcl.2025.130166_bb0015","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","article-title":"Targeting the cell cycle: A new approach to cancer therapy","volume":"23","author":"Schwartz","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bmcl.2025.130166_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bmcl.2025.130166_bb0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/cb500135f","article-title":"An Inhibitor\u2019s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States","volume":"9","author":"Echalier","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"10.1016\/j.bmcl.2025.130166_bb0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"Hydbring","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bmcl.2025.130166_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcell.2019.00023","article-title":"Immunomodulatory roles of cell cycle regulators","volume":"7","author":"Laphanuwat","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.bmcl.2025.130166_bb0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.bmcl.2025.130166_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130166_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting cyclin-dependent kinases in human cancers: From small molecules to peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130166_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000863","article-title":"Cdk2 is required for p53-independent G2\/M checkpoint control","volume":"6","author":"Chung","year":"2010","journal-title":"PLoS Genet."},{"issue":"31","key":"10.1016\/j.bmcl.2025.130166_bb0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/onc.2008.74","article-title":"Cyclin A\/cdk2 coordinates centrosomal and nuclear mitotic events","volume":"27","author":"De Boer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2025.130166_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.774845","article-title":"Cyclin E2\/CDK2: DNA Replication, Replication Stress and Genomic Instability","volume":"9","author":"Fagundes","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.bmcl.2025.130166_bb0070","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/13543776.2015.1045414","article-title":"Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009\u20132014)","volume":"25","author":"Malinkova","year":"2015","journal-title":"Expert Opin Ther Pat."},{"issue":"9","key":"10.1016\/j.bmcl.2025.130166_bb0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/mend.11.9.9977","article-title":"CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells","volume":"11","author":"Teixeira","year":"1997","journal-title":"Mol. Endocrinol."},{"issue":"33","key":"10.1016\/j.bmcl.2025.130166_bb0080","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1038\/onc.2009.170","article-title":"Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms","volume":"28","author":"Satyanarayana","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130166_bb0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.0106-9543.2002.01629.x","article-title":"Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma","volume":"22","author":"Li","year":"2002","journal-title":"Liver"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130166_bb0090","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1128\/MCB.21.8.2755-2766.2001","article-title":"S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells","volume":"21","author":"Hu","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.bmcl.2025.130166_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1054\/drup.2001.0224","article-title":"Perspectives for cancer therapies with cdk2 inhibitors","volume":"4","author":"Wadler","year":"2001","journal-title":"Drug Resist. Updat."},{"issue":"9","key":"10.1016\/j.bmcl.2025.130166_bb0100","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bmcl.2025.130166_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015\u20132019)","volume":"29","author":"Sanchez-Martinez","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bmcl.2025.130166_bb0110","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/13543776.2015.1045414","article-title":"Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009\u20132014)","volume":"25","author":"Malinkova","year":"2015","journal-title":"Expert Opinion on Therap. Pat."},{"issue":"2","key":"10.1016\/j.bmcl.2025.130166_bb0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","article-title":"Targeting CDK2 in cancer: challenges and opportunities for therapy","volume":"25","author":"Tadesse","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130166_bb0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.6023\/cjoc201410039","article-title":"Rencent Advances in Cyclin-Dependent Kinase Inhibitors with Purine Scaffold","volume":"35","author":"Zhang","year":"2015","journal-title":"Chinese J. Org. Chem."},{"issue":"18","key":"10.1016\/j.bmcl.2025.130166_bb0125","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1021\/jm060216x","article-title":"Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity","volume":"49","author":"Pratt","year":"2006","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2025.130166_bb0130","first-page":"135","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.bmcl.2025.130166_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130166_bb0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bmcl.2025.130166_bb0145","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood.V116.21.2999.2999","article-title":"CYC065, a potent derivative of seliciclib is active in multiple myeloma in preclinical studies","volume":"116","author":"Pozzi","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130166_bb0150","first-page":"S7","article-title":"Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)","volume":"78","author":"Do","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bmcl.2025.130166_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234103","article-title":"Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer","volume":"15","author":"Frame","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2025.130166_bb0160","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.clml.2015.04.027","article-title":"CYC065, potential therapeutic agent for AML and MLL leukaemia","volume":"15","author":"Frame","year":"2015","journal-title":"Cl Lymph Myelom Leuk."},{"issue":"1\u20132","key":"10.1016\/j.bmcl.2025.130166_bb0165","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine","volume":"243","author":"DeAzevedo","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bmcl.2025.130166_bb0170","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1126\/science.abn7565","article-title":"Nickel-catalyzed hydrogenative coupling of nitriles and amines for general amine synthesis","volume":"376","author":"Chandrashekhar","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130166_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41420-021-00496-y","article-title":"Interrogation of novel CDK2\/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML","volume":"7","author":"Chantkran","year":"2021","journal-title":"Cell Death Dis."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:07:06Z","timestamp":1762344426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"alternative-id":["S0960894X25000757"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130166","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of 9H-purine scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130166"}}